Note: The following is a summary of a letter dated Feb. 27, 2018, from the US Food and Drug Administration (FDA) to CSL Behring. You can read the original letter here. The FDA has advised CSL Behring that the company鈥檚 promotional materials make misleading claims about the effectiveness of its Idelvion (Factor IX) product. 鈥淪uch […]